This inventor holds 2 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: A2a Pharmaceuticals, Inc., Oncocube Therapeutics LLC. Active years: 2023-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 2 
2 out of 2 Years Active: 2023-2024
Title: Erden Banoglu: Innovator in Cancer Treatment
Introduction
Erden Banoglu is a prominent inventor based in Ankara, Turkey. He has made significant contributions to the field of cancer treatment through his innovative research and development of novel therapeutic agents. With a total of two patents to his name, Banoglu is recognized for his dedication to advancing medical science.
Latest Patents
Banoglu's latest patents focus on compositions and methods for treating cancer. One of his notable inventions includes inhibitors of TACC, which are designed to treat diseases and disorders related to TACC. Another significant patent is for a highly potent TACC3 inhibitor, specifically the chemotype 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (BO-264). This compound targets the TACC3 protein with high potency, serving as a mitotic blocker for the treatment of breast cancer and potentially other types of cancer.
Career Highlights
Throughout his career, Banoglu has worked with several notable companies, including A2A Pharmaceuticals, Inc. and Oncocube Therapeutics LLC. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in oncology.
Collaborations
Banoglu has collaborated with talented individuals such as Burcu Caliskan and Ozgur Sahin. These partnerships have enhanced his research efforts and fostered innovation in cancer treatment.
Conclusion
Erden Banoglu is a dedicated inventor whose work in cancer treatment is paving the way for new therapeutic options. His innovative patents and collaborations highlight his commitment to improving patient outcomes in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile